Evidence map›Paper›PMID 39747450›Full record

ArticleScientific reports2025

Machine learning-based analysis of microfluidic device immobilized C. elegans for automated developmental toxicity testing.

Andrew DuPlissis, Abhishri Medewar, Evan Hegarty, Adam Laing, Amber Shen, Sebastian Gomez, Sudip Mondal, Adela Ben-Yakar

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. High-Throughput Toxicity Screening withEnvironmental science & technology · 2026
    Review
  4. Review
  5. HarnessingSensors (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Andrew DuPlissisvivoVerse, LLC, Austin, TX, 78731, USA.
Abhishri MedewarvivoVerse, LLC, Austin, TX, 78731, USA.
Evan HegartyvivoVerse, LLC, Austin, TX, 78731, USA.
Adam LaingvivoVerse, LLC, Austin, TX, 78731, USA.
Amber ShenvivoVerse, LLC, Austin, TX, 78731, USA.
Sebastian GomezvivoVerse, LLC, Austin, TX, 78731, USA.
Sudip MondalvivoVerse, LLC, Austin, TX, 78731, USA. sudip.mondal@vivoverse.com.
Adela Ben-YakarvivoVerse, LLC, Austin, TX, 78731, USA. ben-yakar@mail.utexas.edu.

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Aric L Daul, Ann E. Rougvie · 2012 to 2026
$7.5M
A Multiwell Plate Format Microfluidic Immobilization Chip for High-Content Imaging of Whole Animals for in vivoNeurotoxicology TestingR44MH118841 · NIMH · VIVOVERSE, LLC · PI HEGARTY, EVAN · 2020 to 2022
$2.2M
The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans PopulationsR44ES033579 · NIEHS · VIVOVERSE, LLC · PI HEGARTY, EVAN · 2023 to 2024
$1.8M
A multiwell plate format microfluidic immobilization chip for high-content imaging of whole animalsR43MH118841 · NIMH · VIVOVERSE, LLC · PI HEGARTY, EVAN · 2018 to 2019
$273k
The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans PopulationsR43ES033579 · NIEHS · VIVOVERSE, LLC · PI HEGARTY, EVAN · 2021 to 2021
$254k
NIEHS NIH HHS R43 ES033579NIEHS NIH HHS R43ES033579NIEHS NIH HHS R44 ES033579NIH HHS P40 OD010440NIMH NIH HHS R43 MH118841NIMH NIH HHS R43MH118841NIMH NIH HHS R44 MH118841
6 · The paper itself

Abstract

Developmental toxicity (DevTox) tests evaluate the adverse effects of chemical exposures on an organism's development. Although current testing primarily relies on large mammalian models, the emergence of new approach methodologies (NAMs) is encouraging industries and regulatory agencies to evaluate novel assays. C. elegans have emerged as NAMs for rapid toxicity testing because of its biological relevance and suitability to high throughput studies. However, current low-resolution and labor-intensive methodologies prohibit its application for sub-lethal DevTox studies at high throughputs. With the recent advent of the large-scale microfluidic device, vivoChip, we can now rapidly collect 3D high-resolution images of ~ 1000 C. elegans from 24 different populations. While data collection is rapid, analyzing thousands of images remains time-consuming. To address this challenge, we developed a machine-learning (ML)-based image analysis platform using a 2.5D U-Net architecture (vivoBodySeg) that accurately segments C. elegans in images obtained from vivoChip devices, achieving a Dice score of 97.80%. vivoBodySeg processes 36 GB data per device, phenotyping multiple body parameters within 35 min on a desktop PC. This analysis is ~ 140 × faster than the manual analysis. This ML approach delivers highly reproducible DevTox parameters (4-8% CV) to assess the toxicity of chemicals with high statistical power.

Indexed as

Caenorhabditis elegansLab-On-A-Chip DevicesMachine LearningToxicity TestsAnimalsImage Processing, Computer-AssistedC. elegansDevelopmental toxicityFew-shot learningHigh-throughput screeningMicrofluidicsU-Net

Identifiers

PMID39747450
PMCPMC11696900

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.